Abstract
Background
Morphine is widely used in cancer care, and understanding the concerns and perceptions of patients, family and friends is vital to managing pain and distress effectively. The ‘myths of morphine’ have frequently been discussed in medical literature, yet the extent to which such views are held is not clear. This qualitative project explores the perceptions and attitudes of the wider community towards morphine use in cancer care, to understand this ‘mythology’ according to those who in the future may themselves require its use.
Methods
Semi-structured interviews were held with patients presenting to a metropolitan general practice clinic in Melbourne, Australia. A grounded theory framework underpinned the data collection and thematic analysis undertaken.
Results
Interviewees (15) were aged 24–81, with a variety of experiences with cancer care and previous morphine use. Interviewees were highly supportive of morphine use in cancer care, with this attitude founded on the perceived severity of cancer pain and the powerful nature of morphine. They described a number of reasons morphine may be used in cancer care: to treat pain, to enable peace and also as a treatment for cancer.
Conclusion
The public view of morphine to emerge from this study is markedly different from that discussed in the myths of morphine. It is viewed as a medication that has the ability to provide peace and control both pain and the course of cancer. The participants in this study described a wish for greater involvement in pain control decisions, perceiving morphine as a facilitator rather than a barrier to good cancer care.
Similar content being viewed by others
References
Clark D (1999) ‘Total pain’, disciplinary power and the body in the work of Cicely Saunders, 1958-1967. Soc Sci Med 49(6):727–736
Potter VT, Wiseman CE, Dunn SM, Boyle FM (2003) Patient barriers to optimal cancer pain control. Psychooncology 12(2):153–160
Manderson DRA (1988) The first loss of freedom: early opium laws in Australia. Aust Drug Alcohol Rev 7(4):439–453
Grant M, Philip J, Ugalde A (2014) A functional dependence? A social history of the medical use of morphine in Australia. Med J Aust 200(4):230–232
Flemming K (2010) The use of morphine to treat cancer-related pain: a synthesis of quantitative and qualitative research. J Pain Symptom Manag 39(1):139–154
Reid CM, Gooberman-Hill R, Hanks GW (2008) Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 19(1):44–48
Maltoni M (2008) Opioids, pain, and fear. Ann Oncol 19(1):5–7
Shoemaker PJ (1989) Communication campaigns about drugs: government, media, and the public: L. Erlbaum Associates, Hillsdale, NJ
Oxberry SG, Jones L, Clark AL, Johnson MJ (2012) Attitudes to morphine in chronic heart failure patients. Postgrad Med J 88(1043):515–521
Zenz M (1991) Morphine myths: sedation, tolerance, addiction. Postgrad Med J 67:S100
Forbes K (2006) Opioids: beliefs and myths. J Pain Palliat Care Pharmacother 20(3):33–35
Doyle D (1991) Morphine: myths, morality and economics. Postgrad Med J 67(Suppl 2):S70–S73
Elliott TE, Elliott BA (1992) Physician attitudes and beliefs about use of morphine for cancer pain. J Pain Symptom Manag 7(3):141–148
Lossignol DA (1993) Pitfalls in the use of opiates in treatment of cancer pain. Support Care Cancer 1(5):256–258
Ersek M, Miller Kraybill B, Du Pen A (1999) Factors hindering patients’ use of medications for cancer pain. Cancer Pract 7(5):226–232
Bennett MI, Graham J, Schmidt-Hansen M, Prettyjohns M, Arnold S (2012) Prescribing strong opioids for pain in adult palliative care: summary of NICE guidance. BMJ Br Med J 344:42
Ward SE, Goldberg N, Miller-McCauley V, Mueller C, Nolan A, Pawlik-Plank D et al (1993) Patient-related barriers to management of cancer pain. Pain 52(3):319–324
Gunnarsdottir S, Donovan HS, Serlin RC, Voge C, Ward S (2002) Patient-related barriers to pain management: the barriers questionnaire II (BQ-II). Pain 99(3):385–396
Paice JA, Toy C, Shott S (1998) Barriers to cancer pain relief: fear of tolerance and addiction. J Pain Symptom Manag 16(1):1–9
Seymour JE, Bellamy G, Gott M, Ahmedzai SH, Clark D (2002) Good deaths, bad deaths: older people’s assessments of the risks and benefits of morphine and terminal sedation in end-of-life care. Health Risk Soc 4(3):287–303
Halldórsdóttir S, Hamrin E (1996) Experiencing existential changes: the lived experience of having cancer. Cancer Nurs 19(1):29–36
Zenz M, Sorge J (1991) Is the therapeutic use of opioids adversely affected by prejudice and law? In: Senn H-J, Glaus A (eds). Supportive care in cancer patients II. Recent results in cancer research. 121. Springer, Heidelberg, pp 43–50
Momen N, Hadfield P, Harrison K, Barclay S (2012) Managing pain in advanced cancer: a survey of United Kingdom general practitioners and community nurses. J Pain Symptom Manage 46(3):345–54
Britt H, Miller GC, Charles J, Henderson J, Bayram C, Pan Y, et al (2009) General practice activity in Australia 2008-09: Australian Institute of Health and Welfare, and University of Sydney
Vafiadis P (2001) Mutual care in palliative medicine: a story of doctors and patients. Roseville, N.S.W. McGraw-Hill, Australia
Conflict of interest
Matthew Grant was previously employed as a pharmacovigilance physician by MSD; however, he has no ongoing relationship with the company.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grant, M., Ugalde, A., Vafiadis, P. et al. Exploring the myths of morphine in cancer: views of the general practice population. Support Care Cancer 23, 483–489 (2015). https://doi.org/10.1007/s00520-014-2379-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2379-9